R&D Cost Increase May Reflect Comparative Trials; Can Biotech Keep Up?
Executive Summary
The sharp increase in the average spending on clinical trials in the pharmaceutical industry may reflect increasing pressure to demonstrate advantages over marketed products, Tufts Center for the Study of Drug Development Director of Economic Analysis Joseph DiMasi, PhD, suggested during a Nov. 30 conference in Philadelphia
You may also be interested in...
R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME
Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12
R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME
Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12
Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”
Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17